More about

Pembrolizumab

News
December 15, 2023
2 min read
Save

FDA approves enfortumab vedotin with pembrolizumab for advanced bladder cancer

FDA approves enfortumab vedotin with pembrolizumab for advanced bladder cancer

The FDA approved enfortumab vedotin-ejfv in combination with pembrolizumab for patients with locally advanced or metastatic urothelial cancer, according to an agency press release.

News
December 07, 2023
3 min read
Save

Pembrolizumab plus olaparib does not extend survival in triple-negative breast cancer

Pembrolizumab plus olaparib did not improve outcomes among patients with locally recurrent inoperable or metastatic triple-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

News
December 06, 2023
2 min read
Save

Immunotherapy-chemotherapy combination increases response in high-risk breast cancer

Immunotherapy-chemotherapy combination increases response in high-risk breast cancer

SAN ANTONIO — An immunotherapy-chemotherapy combination conferred benefit for certain patients with high-risk breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

News
December 01, 2023
2 min read
Save

Selpercatinib delivers superior outcomes, may ‘reduce the burden of NSCLC’

Selpercatinib delivers superior outcomes, may ‘reduce the burden of NSCLC’

Treatment with selpercatinib for advanced RET fusion-positive non-small cell lung cancer resulted in significantly longer PFS compared with platinum-based chemotherapy with or without pembrolizumab, study results showed.

News
November 30, 2023
2 min read
Save

HCPs welcome approval of updated Novavax COVID-19 vaccine

HCPs welcome approval of updated Novavax COVID-19 vaccine

A recent analysis of global conversations involving almost 1,500 health care professionals on social media from Oct. 1 to 31 has revealed a predominantly positive reaction to the FDA’s approval of Novavax’s updated COVID-19 vaccine.

News
November 21, 2023
2 min read
Save

Trial eligibility linked to better outcomes after immunotherapy for renal cell carcinoma

Trial eligibility linked to better outcomes after immunotherapy for renal cell carcinoma

NASHVILLE, Tenn. — Patients with renal cell carcinoma who met eligibility criteria for pivotal phase 3 trials achieved significantly longer survival after combination immunotherapy than trial-ineligible patients, according to study results.

News
November 16, 2023
1 min read
Save

FDA approves Keytruda with chemotherapy for gastric, gastroesophageal cancers

FDA approves Keytruda with chemotherapy for gastric, gastroesophageal cancers

The FDA approved pembrolizumab for use with chemotherapy to treat HER2-negative gastric or gastroesophageal junction adenocarcinoma.

News
November 14, 2023
2 min read
Save

Adjuvant pembrolizumab well tolerated in high-risk renal cell carcinoma

Adjuvant pembrolizumab well tolerated in high-risk renal cell carcinoma

NASHVILLE, Tenn. — Adjuvant pembrolizumab appeared well tolerated among patients with high-risk renal cell carcinoma after nephrectomy, according to study results.

News
November 09, 2023
1 min read
Save

FDA amends gastric cancer indication for Keytruda

FDA amends gastric cancer indication for Keytruda

The FDA revised an existing indication of pembrolizumab for the first-line treatment of certain patients with gastric or gastroesophageal junction adenocarcinoma.

News
November 08, 2023
2 min watch
Save

VIDEO: Adagrasib, pembrolizumab shows ‘encouraging’ activity in KRAS G12C-mutated NSCLC

VIDEO: Adagrasib, pembrolizumab shows &lsquo;encouraging&rsquo; activity in <i>KRAS</i> G12C-mutated NSCLC

MADRID — Pasi Jänne, MD, PhD, discussed the “encouraging” clinical activity of adagrasib with pembrolizumab in patients with KRAS G12C-mutated advanced non-small cell lung cancer in a video interview with Healio at ESMO Congress.

View more